Cargando…
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
Excessive Ca(2+) currents via N-methyl-D-aspartate receptors (NMDARs) have been implicated in many disorders. Uncompetitive NMDAR channel blockers are an emerging class of drugs in clinical use for major depressive disorder (MDD) and other neuropsychiatric diseases. The pharmacological characterizat...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414551/ https://www.ncbi.nlm.nih.gov/pubmed/36015145 http://dx.doi.org/10.3390/ph15080997 |
_version_ | 1784776015789162496 |
---|---|
author | Bettini, Ezio Stahl, Stephen M. De Martin, Sara Mattarei, Andrea Sgrignani, Jacopo Carignani, Corrado Nola, Selena Locatelli, Patrizia Pappagallo, Marco Inturrisi, Charles E. Bifari, Francesco Cavalli, Andrea Alimonti, Andrea Pani, Luca Fava, Maurizio Traversa, Sergio Folli, Franco Manfredi, Paolo L. |
author_facet | Bettini, Ezio Stahl, Stephen M. De Martin, Sara Mattarei, Andrea Sgrignani, Jacopo Carignani, Corrado Nola, Selena Locatelli, Patrizia Pappagallo, Marco Inturrisi, Charles E. Bifari, Francesco Cavalli, Andrea Alimonti, Andrea Pani, Luca Fava, Maurizio Traversa, Sergio Folli, Franco Manfredi, Paolo L. |
author_sort | Bettini, Ezio |
collection | PubMed |
description | Excessive Ca(2+) currents via N-methyl-D-aspartate receptors (NMDARs) have been implicated in many disorders. Uncompetitive NMDAR channel blockers are an emerging class of drugs in clinical use for major depressive disorder (MDD) and other neuropsychiatric diseases. The pharmacological characterization of uncompetitive NMDAR blockers in clinical use may improve our understanding of NMDAR function in physiology and pathology. REL-1017 (esmethadone-HCl), a novel uncompetitive NMDAR channel blocker in Phase 3 trials for the treatment of MDD, was characterized together with dextromethorphan, memantine, (±)-ketamine, and MK-801 in cell lines over-expressing NMDAR subtypes using fluorometric imaging plate reader (FLIPR), automated patch-clamp, and manual patch-clamp electrophysiology. In the absence of Mg(2+), NMDAR subtypes NR1-2D were most sensitive to low, sub-μM glutamate concentrations in FLIPR experiments. FLIPR Ca(2+) determination demonstrated low μM affinity of REL-1017 at NMDARs with minimal subtype preference. In automated and manual patch-clamp electrophysiological experiments, REL-1017 exhibited preference for the NR1-2D NMDAR subtype in the presence of 1 mM Mg(2+) and 1 μM L-glutamate. Tau off and trapping characteristics were similar for (±)-ketamine and REL-1017. Results of radioligand binding assays in rat cortical neurons correlated with the estimated affinities obtained in FLIPR assays and in automated and manual patch-clamp assays. In silico studies of NMDARs in closed and open conformation indicate that REL-1017 has a higher preference for docking and undocking the open-channel conformation compared to ketamine. In conclusion, the pharmacological characteristics of REL-1017 at NMDARs, including relatively low affinity at the NMDAR, NR1-2D subtype preference in the presence of 1 mM Mg(2+), tau off and degree of trapping similar to (±)-ketamine, and preferential docking and undocking of the open NMDAR, could all be important variables for understanding the rapid-onset antidepressant effects of REL-1017 without psychotomimetic side effects. |
format | Online Article Text |
id | pubmed-9414551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94145512022-08-27 Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors Bettini, Ezio Stahl, Stephen M. De Martin, Sara Mattarei, Andrea Sgrignani, Jacopo Carignani, Corrado Nola, Selena Locatelli, Patrizia Pappagallo, Marco Inturrisi, Charles E. Bifari, Francesco Cavalli, Andrea Alimonti, Andrea Pani, Luca Fava, Maurizio Traversa, Sergio Folli, Franco Manfredi, Paolo L. Pharmaceuticals (Basel) Article Excessive Ca(2+) currents via N-methyl-D-aspartate receptors (NMDARs) have been implicated in many disorders. Uncompetitive NMDAR channel blockers are an emerging class of drugs in clinical use for major depressive disorder (MDD) and other neuropsychiatric diseases. The pharmacological characterization of uncompetitive NMDAR blockers in clinical use may improve our understanding of NMDAR function in physiology and pathology. REL-1017 (esmethadone-HCl), a novel uncompetitive NMDAR channel blocker in Phase 3 trials for the treatment of MDD, was characterized together with dextromethorphan, memantine, (±)-ketamine, and MK-801 in cell lines over-expressing NMDAR subtypes using fluorometric imaging plate reader (FLIPR), automated patch-clamp, and manual patch-clamp electrophysiology. In the absence of Mg(2+), NMDAR subtypes NR1-2D were most sensitive to low, sub-μM glutamate concentrations in FLIPR experiments. FLIPR Ca(2+) determination demonstrated low μM affinity of REL-1017 at NMDARs with minimal subtype preference. In automated and manual patch-clamp electrophysiological experiments, REL-1017 exhibited preference for the NR1-2D NMDAR subtype in the presence of 1 mM Mg(2+) and 1 μM L-glutamate. Tau off and trapping characteristics were similar for (±)-ketamine and REL-1017. Results of radioligand binding assays in rat cortical neurons correlated with the estimated affinities obtained in FLIPR assays and in automated and manual patch-clamp assays. In silico studies of NMDARs in closed and open conformation indicate that REL-1017 has a higher preference for docking and undocking the open-channel conformation compared to ketamine. In conclusion, the pharmacological characteristics of REL-1017 at NMDARs, including relatively low affinity at the NMDAR, NR1-2D subtype preference in the presence of 1 mM Mg(2+), tau off and degree of trapping similar to (±)-ketamine, and preferential docking and undocking of the open NMDAR, could all be important variables for understanding the rapid-onset antidepressant effects of REL-1017 without psychotomimetic side effects. MDPI 2022-08-13 /pmc/articles/PMC9414551/ /pubmed/36015145 http://dx.doi.org/10.3390/ph15080997 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bettini, Ezio Stahl, Stephen M. De Martin, Sara Mattarei, Andrea Sgrignani, Jacopo Carignani, Corrado Nola, Selena Locatelli, Patrizia Pappagallo, Marco Inturrisi, Charles E. Bifari, Francesco Cavalli, Andrea Alimonti, Andrea Pani, Luca Fava, Maurizio Traversa, Sergio Folli, Franco Manfredi, Paolo L. Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors |
title | Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors |
title_full | Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors |
title_fullStr | Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors |
title_full_unstemmed | Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors |
title_short | Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors |
title_sort | pharmacological comparative characterization of rel-1017 (esmethadone-hcl) and other nmdar channel blockers in human heterodimeric n-methyl-d-aspartate receptors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414551/ https://www.ncbi.nlm.nih.gov/pubmed/36015145 http://dx.doi.org/10.3390/ph15080997 |
work_keys_str_mv | AT bettiniezio pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT stahlstephenm pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT demartinsara pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT mattareiandrea pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT sgrignanijacopo pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT carignanicorrado pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT nolaselena pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT locatellipatrizia pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT pappagallomarco pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT inturrisicharlese pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT bifarifrancesco pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT cavalliandrea pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT alimontiandrea pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT paniluca pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT favamaurizio pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT traversasergio pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT follifranco pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors AT manfredipaolol pharmacologicalcomparativecharacterizationofrel1017esmethadonehclandothernmdarchannelblockersinhumanheterodimericnmethyldaspartatereceptors |